Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
18.17 ^USD	-4.69%		-0.38%	-85.06%

Jun. 30	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index	CI
Jun. 30	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index	CI

Sector Update: Health Care Stocks Rise Late Afternoon

Published on 03/18/2025 at 16:00, updated on 03/18/2025 at 16:07

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index	Jun. 30	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index	Jun. 30	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2500 Value Index	Jun. 30	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 1000 Value Index	Jun. 30	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000E Value Index	Jun. 29	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Benchmark	Jun. 29	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2500 Value Benchmark	Jun. 29	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Benchmark	Jun. 29	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Small Cap Comp Value Benchmark	Jun. 29	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000E Value Benchmark	Jun. 29	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 1000 Value Benchmark	Jun. 29	CI
Sarepta Therapeutics' Elevidys Under Investigation by US FDA Following Patient Deaths	Jun. 25	MT
FDA investigates patient deaths after treatment with Sarepta's gene therapy	Jun. 24	RE
FDA investigates patient deaths after treatment with Sarepta's gene therapy	Jun. 24	RE
Sector Update: Health Care Stocks Retreat Late Afternoon	Jun. 20	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Jun. 20	MT
Sarepta Therapeutics Shares Decline After Downgrade From William Blair	Jun. 20	MT
The Two-Week Ticking Clock	Jun. 20
William Blair Downgrades Sarepta Therapeutics to Market Perform From Outperform	Jun. 20	MT
Analyst recommendations: Apple, Dow, Coinbase, Comcast, The Gap…	Jun. 20
Goldman Sachs Downgrades Sarepta Therapeutics to Neutral From Buy, Adjusts Price Target to $29 From $100	Jun. 18	MT
TD Cowen Downgrades Sarepta Therapeutics to Hold From Buy, Cuts Price Target to $24 From $62	Jun. 18	MT
A Rate Decision in a War Drumbeat	Jun. 18
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research…	Jun. 18

Chart Sarepta Therapeutics, Inc.

Duration

Period

SRPT: Dynamic Chart

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Employees

1,372

Sector

Pharmaceuticals

Calendar

Jul. 29 - Q2 2025 Earnings Release (Projected)

More about the company